These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

251 related items for PubMed ID: 37972706

  • 1. Anti-fibrotic effects of nintedanib on lung fibroblasts derived from patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs).
    Joannes A, Voisin T, Morzadec C, Letellier A, Gutierrez FL, Chiforeanu DC, Le Naoures C, Guillot S, De Latour BR, Rouze S, Jaillet M, Crestani B, Wollin L, Jouneau S, Vernhet L.
    Pulm Pharmacol Ther; 2023 Dec; 83():102267. PubMed ID: 37972706
    [Abstract] [Full Text] [Related]

  • 2. Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases.
    Wollin L, Distler JHW, Redente EF, Riches DWH, Stowasser S, Schlenker-Herceg R, Maher TM, Kolb M.
    Eur Respir J; 2019 Sep; 54(3):. PubMed ID: 31285305
    [Abstract] [Full Text] [Related]

  • 3. Arsenic trioxide inhibits the functions of lung fibroblasts derived from patients with idiopathic pulmonary fibrosis.
    Joannes A, Morzadec C, Duclos M, Gutierrez FL, Chiforeanu DC, Le Naoures C, De Latour B, Rouzé S, Wollin L, Jouneau S, Vernhet L.
    Toxicol Appl Pharmacol; 2022 Apr 15; 441():115972. PubMed ID: 35276128
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Using Data on Survival with Idiopathic Pulmonary Fibrosis to Estimate Survival with Other Types of Progressive Fibrosis Interstitial Lung Disease: A Bayesian Framework.
    Langford B, Diamantopoulos A, Maher TM, Inoue Y, Rohr KB, Baldwin M.
    Adv Ther; 2022 Feb 15; 39(2):1045-1054. PubMed ID: 34957531
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Use of antifibrotic drugs in interstitial lung disease].
    Kreutz CP, Gesierich W, Behr J, Kneidinger N.
    Dtsch Med Wochenschr; 2022 Oct 15; 147(21):1383-1390. PubMed ID: 36279864
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. MARCH8 downregulation modulates profibrotic responses including myofibroblast differentiation.
    Guo X, Adeyanju O, Olajuyin AM, Mandlem V, Sunil C, Adewumi J, Huang S, Tucker TA, Idell S, Qian G.
    Am J Physiol Cell Physiol; 2023 Nov 01; 325(5):C1190-C1200. PubMed ID: 37661917
    [Abstract] [Full Text] [Related]

  • 17. The dorsal muscle group area at the T12 vertebral level as a risk factor for tolerability of nintedanib in patients with idiopathic pulmonary fibrosis or other progressive fibrosing interstitial lung diseases.
    Ono M, Kobayashi S, Masakazu H, Ishida M, Sato H, Okutomo K, Shirai Y, Takahashi K, Yamada M, Fujino N, Yamanda S, Yanai M.
    Medicine (Baltimore); 2024 Jul 12; 103(28):e38920. PubMed ID: 38996147
    [Abstract] [Full Text] [Related]

  • 18. Real-life prevalence of progressive fibrosing interstitial lung diseases.
    Gagliardi M, Berg DV, Heylen CE, Koenig S, Hoton D, Tamirou F, Pieters T, Ghaye B, Froidure A.
    Sci Rep; 2021 Dec 14; 11(1):23988. PubMed ID: 34907290
    [Abstract] [Full Text] [Related]

  • 19. Pharmacological management of progressive-fibrosing interstitial lung diseases: a review of the current evidence.
    Richeldi L, Varone F, Bergna M, de Andrade J, Falk J, Hallowell R, Jouneau S, Kondoh Y, Morrow L, Randerath W, Strek M, Tabaj G.
    Eur Respir Rev; 2018 Dec 31; 27(150):. PubMed ID: 30578333
    [Abstract] [Full Text] [Related]

  • 20. Nationwide epidemiologic study for fibrosing interstitial lung disease (F-ILD) in South Korea: a population-based study.
    Joung KI, Park H, Park S, Shin JY, Kim YH.
    BMC Pulm Med; 2023 Mar 22; 23(1):98. PubMed ID: 36949407
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.